Compumedics Limited · ASX:CMP
Compumedics — Investor Presentation (April 2005)
22 slides from Compumedics's investor presentation, April 2005
Slide 1: Investor Presentation April 2005
Investor Presentation April 2005
Slide 2: Outline
Outline ® Compumedics’ introduction of financial highlights : Performance highlights - Growth profile.
Slide 3: Introduction - Key Milestones
Introduction - Key Milestones a Compumedics has.an.impressive.track.record.of achievement: 995°" 4995 1995 1996 1997 1999 2000 2000. 2002, , ‘Synamp2 and IPS “The pre-eminent Ay scoring protece! Téeijin appointed as Japanese distributer NASA contracts won Sleep Heart Health Study awarded JAFCO equit
Slide 4: Introduction - The Sleep Industry
Introduction - The Sleep Industry There--are--84--known-~-sleep-—-disorders-ranging--from- snoring -to- obstructive sleep apnea. 84 known sleep disorders. Obstructive sleep apnea (25%t+), PLM (10%), Insomnia-(7%). ‘Over 20 million people i in the USA are estimated to suffer from sleep apnea alone.
Slide 5: Financial Highlights
® Loss at the NPAT line of $0.8m compares with last year’s $1.1m profit. REVENUE ® Record-revenues-of $49.2m for-the-half. CASH- a Positive 6pérating cash at $0.7m. "@”- Europe business strengthened and is.now ready for executi building of our sales and service infrastructure. CONTROLS - ventory at
Slide 6: Performance Highlights - Dec end
Performance a Aighlights-— — Dec end 04 Acquisition of DWLi in Singen, Germany. European base now established, positioning . Europe for rapid growth outlook. i “Contributed $2.4m revenue forthe period from 1 : September, 2004, : 2 -Key management secured by DWL b isiness founders. » 24 other staff.
Slide 7: Growth Profile - Historical Sales Graph
Growth Profile - Historical Sales Graph AUSm 25 20 = 45 a | : a : . . . AU ry “a — : deel TH“ 2H99°THOO 2HOO 1HOT 2HOT 1HOZ 2HO2 THOS 2HO3 1HO4 2HO4 Thos a Export Sales m Domestic Sales. l! Other Income 340 +68
Slide 8: Growth Profile - Strong growth continues in USA
Growth Profile - Strong growth continues in USA 2004. Europe Asia 14% 23%
Slide 9: Growth Profile - Compumedics Global Company
_ Growth Profile - Compumedics — Global Company W Heal Cline: Geo (aos @ Existing Office Locations: Sjinay (Suaralc) | Ei huce UGA) | Shapers (Singapore) | tari A Bingen Ghermwny’ Diswriburors: Ai Siew BM Newrnscan th Mearosctence GON WF Maurenciuien!Sieep WW Stourssimnce/Meurosean Ti-Btnep@Aeurasca
Slide 10: Growth Profile - Strategies
Growth Profile - Strategies" * International market expansion of the core sleep business ® Expansion of core sleep.diagnostic and -_ monitoring technology into the associated fields of neurology and cardiology. Expand recurring revenue base (sensors, electrodes and other consumables). ~ Growth opr d
Slide 11: Growth Profile - Some market facts
Growth Profile - Some market facts: Compumedics ~ Clinical sleet: and EES oceertentennne ® 40% of the Australian Clinical EEG Market and 70% of the Australian Sleep Diagnostics Market. w® 10% USA market share and growing in sleep diagnostics. ® Developed: and installed Australia’s first computerised
Slide 12: Current Market Share
Gurrent Market Share: 16% Large growth potential. In the next 12 months we expect to grow our share of the brain research market in Europe by 50% Current Market Share: Less than 1% inthe noxt 12 months we expect fo grow our share of the neuro diagnostics market by 100% Surrent Market Share ~ 7% In t
Slide 13: Growth Profile - A Big Market to Grow In
Growth Profile - A Big Market to Grow Ine. High investment (18% of revenues) levels.in R&D and product development. continue,-.as.a-reflection.of.a.strong-sales.outlook.and.preduct pipeline. Estimated global market val
Slide 14: Growth Profile - Distribution Channels
Growth Profile - Distribution Channels ® USA sales are made direct to end-user customers by Compumedics staff. ® Australian sales are made direct by Compumedics staff. ® “European sleep sales are undertaken by a network of - distributors. Our main sleep distributor is Draeger Medical. Asian sales ar
Slide 15: Core Products
Core Products — ae - @ New generation laboratory based diagnostic — product for both full polysomnography (PSG) “sleep” studies.and.or.separate EEG studies. World leading portable diagnostic device with wireless capability for both sleep. and general patient monitoring. : mbined Sleep and CHF monito
Slide 16: Core Products
Core Products of. FAG NOSE sophisticated neurological amplifier. available.on the market. These amplifiers can be combined to obtain up to 256 channels of physiological data. . ® Provides for the acquisition of the EEG and Evoked -Potential-data including a rich set of clinically popular and useful
Slide 17: Core Products - sample
Core Products - sample — Neuroscan PRODUCT USAGE | CUSTOMER’ BENEFITS APPROVAL” PRICE POINT E-Series Sleep diagnosis.) Sleep-aboratories | New technology, FDA, CE, TGA $17,500 and EEG. |-and hospital growing customer monitoring i tase. Siesta Sleep monitoring | Hospitals and-|-Wireless; versatile, |
Slide 18: Core Products - Moving Forward Technologies
Core Products - Moving Forward Technologies
Slide 19: Strategy Working
Strategy Working Building a-global medical diagnostic company =o With Compumedics' core strategic edge beitig Sleep Diagnostics and éraging this technology into related fields inely i esearch, Neuromedical supplies. Combined, these AUD st. 2 billion. lences, Cardiology, Brain . e annual sales of mor
Slide 20: Moving Forward: Business
Moving Forward : Business Revenues expected to be around the $38 to $42m region for year ended June 30, 2005. Earnings after tax.expected to be between $1 million and $3.million for year ended June 30, 2005. Revenue in the second half expected to be stronger over the: first half in 2005 again as gro
Slide 21: Moving Forward: Business (cont)
Moving Forward : Business (con « Europe positioned growth as infrastructure there is- built in a similar way to that of the USA (organic growth.and:continued-integration of DWL business). « The cost efficiency programs and lean processes. “ Expanded and strengthened USA Sales force with more new sal
Slide 22: Recap | Way Forward
Recap | Way Forward won Global technological and product leadership across sleep: diagnostic, ; neurodiagnostic and cardiodiagnostic fields with strong growth opportunity as Compumedics continues to penetrate 1 billion per annum market. 2. Strong product pipelines and technology product leadership p